急性髓系白血病和高危骨髓增生异常综合征中,7+3方案与阿扎胞苷治疗后缓解相关的相对生存相似:四项SWOG研究分析
该分析比较7+3方案与阿扎胞苷治疗急性髓系白血病(AML)和高危骨髓增生异常综合征(MDS)后,完全缓解(CR)带来的绝对和相对总生存(OS)获益。CR在多变量分析中带来相对生存优势,且该相对效应在各研究间相似;CR也带来绝对生存获益,但在阿扎胞苷试验中绝对获益幅度较小。在AML中,CRi与未达CR/CRi的OS相似;在MDS中,CR较HI带来生存优势,HI较失败带来生存优势。
要点
- CR在多变量分析中带来相对生存优势,且该相对效应在各研究间相似。
- CR也带来绝对生存获益,但在阿扎胞苷试验中绝对获益幅度较小。
- 在AML中,CRi与未达CR/CRi的OS相似;在MDS中,CR较HI、HI较失败均带来生存优势。
核心结论
- 无论AML或高危MDS采用7+3还是阿扎胞苷初始治疗,CR的相对生存获益相似。
- 两种治疗下,CR相比CRi或HI均对生存有有利影响。
研究设计与样本
- 比较7+3方案(SWOG S0106,n=301;S1203,n=261;入组≤60岁成人)与阿扎胞苷治疗(S0703,n=133例≥60岁AML患者;S1117,n=277例≥18岁MDS患者)的患者。
- 绝对生存获益采用1年、3年及中位OS评估;相对获益采用单变量和多变量校正的风险比评估。
主要发现
- CR在多变量分析中带来相对生存优势,且该相对效应在各研究间相似。
- CR也带来绝对生存获益,但在阿扎胞苷试验中绝对获益幅度较小。
- 在AML中,CRi与未达CR/CRi的OS相似。
- 在MDS中,CR较HI带来生存优势,HI较失败带来生存优势。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Here we quantify and compare the absolute and relative overall survival (OS) benefits conveyed by complete remission (CR) in AML and high-risk MDS, and by CR with incomplete count recovery (CRi) in AML and by hematologic improvement (HI) in MDS, following treatment with 7 + 3 versus azacytidine. We compared patients receiving 7 + 3 in SWOG studies S0106 (n = 301) and S1203 (n = 261) enrolling adults ≤ 60 years, with patients receiving azacytidine therapies in S0703 (n = 133 AML patients ≥ 60) and S1117 (n = 277 MDS patients ≥ 18). Absolute survival benefit was evaluated with 1-year, 3-year, and median OS; relative benefit was evaluated with univariate and covariate-adjusted hazard ratios. CR conveyed a relative survival advantage in multivariable analysis, with a similar relative effect of CR across studies. CR also conferred an absolute survival benefit, but with a smaller magnitude of absolute benefit in the azacytidine trials. In AML, OS was similar for CRi and failure to achieve CR/CRi. In MDS, CR conferred a survival advantage versus HI and HI versus failure. The relative survival benefit of CR was similar regardless of initial therapy for AML or high-risk MDS. With both therapies, CR has a beneficial effect on survival compared with CRi or HI.
引用
- Othus M, Sekeres MA, Nand S, et al. Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. Leukemia. 2018. PMID: 30315234. doi:10.1038/s41375-018-0275-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。